pp-182 Tablets
Dossier type
CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Comments
Indication: Pediatric myopia progression (axial elongation) in children 6–16 years
Clinical stage: Phase 3
Modality: Small molecule
Mechanism / Target: Adenosine A2A receptor antagonist — stimulates collagen synthesis in scleral fibroblasts, increasing scleral collagen content and mechanical resistance against axial elongation; also modulates adenosine-mediated dopamine/retinal signalling
Route / form: Oral tablet (once or twice daily)
Differentiation: First-in-class oral systemic treatment for myopia control; >20 years compassionate use in Denmark with >1,200 children and strong safety data; novel mechanism vs topical atropine or orthokeratology;
Manufacturer #39199
Ophthalmology-focused biotech (est. 2015) founded via Denmark-India collaboration (Dr. Klaus Trier + Bioplus Life Sciences). Developing the world's first oral therapy for pediatric myopia progression based on 7-methylxanthine. No active co-development partner; wholly owned global Phase 3 programme.
None